Belgium-based Chamaeleo Pharma NV, which works in oncology, has appointed Han Van ‘t Klooster as head of commercial operations, responsible for the commercial launch of the company’s registration-ready product for prostate cancer. Mr Van ‘t Klooster joins the company from Pharmion Europe, which was acquired by Celgene Inc in 2007. Before this, he was director of international marketing for oncology at Chiron Corporation, now part of Novartis.
Chamaeleo Pharma announced the appointment on 2 March 2015.